Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.

Item
http://www.wikidata.org/entity/Q37457809
Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.Reviving the guardian of the genome: Small molecule activators of p53.Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics.Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Salidroside, a Chemopreventive Glycoside, Diminishes Cytotoxic Effect of Cisplatin in Vitro.Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway.The expression of MDM2 in gastrointestinal stromal tumors: immunohistochemical analysis of 35 cases.Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.
P2860

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.

Item
http://www.wikidata.org/entity/Q37457809
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pre-clinical efficacy and syne ...... h cisplatin in ovarian cancer.
@en
Pre-clinical efficacy and syne ...... h cisplatin in ovarian cancer.
@nl
type
label
Pre-clinical efficacy and syne ...... h cisplatin in ovarian cancer.
@en
Pre-clinical efficacy and syne ...... h cisplatin in ovarian cancer.
@nl
prefLabel
Pre-clinical efficacy and syne ...... h cisplatin in ovarian cancer.
@en
Pre-clinical efficacy and syne ...... h cisplatin in ovarian cancer.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Pre-clinical efficacy and syne ...... th cisplatin in ovarian cancer
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932